To elucidate the mechanism through which TKIs, and FOXO reactivation, induce quiescence in primary CML cells, we interrogated a microarray dataset carried out for CML CD34+ cells treated with 150 nM dasatinib for 16 hours (Fig. 3A). This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.